spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  XIMIS 

 HSMN NewsFeed - 22 Nov 2022
Janneke van der Kamp joins Grünenthal as new Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Apr 2022
CellCentric Strengthens Leadership Team
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 16 Dec 2021
Nordic Nanovector appoints Experienced International Life Sciences Executive Sandra Jonsson as Chief Operating Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 15 Dec 2021
Roche Launches the First Infectious Disease Tests and Cobas Omni Utility Channel for Use on the Cobas 5800 System in Countries Accepting the CE Mark
Diagnostics Product Launch
 HSMN NewsFeed - 25 Oct 2021
Medivir Appoints Jens Lindberg as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Apr 2021
Computer-guided surgery with Smith & Nephew's hip replacement implants shown to significantly improve survivorship and increase patient satisfaction compared to conventional surgery
Devices Orthopaedic
 HSMN NewsFeed - 13 Sep 2019
Largest Ever Hip Fracture Fixation Trial in Over 1,000 Patients Demonstrates Unprecedently Low Cut-Out Rates for X-BOLT(R) Device
Devices Orthopaedic
 HSMN NewsFeed - 17 Jan 2019
Asceneuron Appoints Peter Van Vlasselaer as Chairman
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 2 Aug 2018
CALCIVIS Raises £3.15 Million to Fund PMA Approval of the CALCIVIS(R) Imaging System Ahead of a Planned US Launch in 2019
Devices Dental Venture Capital Product Launch
 HSMN NewsFeed - 10 May 2018
Permira Funds To Acquire Corin A Leading Orthopaedic Company
Devices Orthopaedic Mergers & Acquisitions
 HSMN NewsFeed - 24 Nov 2016
Kymab Secures US$100 Million Series C Funding
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 20 Jan 2016
Oncimmune Appoints Greg Stanley as President of Commercial Operations
Diagnostics Oncology Personnel
 HSMN NewsFeed - 3 Sep 2014
Nabriva Therapeutics Appoints Dr Colin Broom as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Feb 2014
GC Aesthetics raises $60M to Fund Global Growth and New Product Development
Devices Dermatology Venture Capital
 HSMN NewsFeed - 3 May 2012
Creabilis Appoints Dr Simon Russell as Chief Business Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Mar 2012
Biosensors Makes Organizational Changes to Senior Management Team to Prepare for Continued Growth
Devices Interventional Cardiology Personnel
 HSMN NewsFeed - 1 Sep 2010
Archimedes Pharma Receives European Marketing Authorisation for PecFent(R) for the Treatment of Breakthrough Cancer Pain
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 16 Jul 2010
James Cook University Hospital Introduces Advanced TomoTherapy(R) Radiation Therapy Treatments
Devices Oncology
 HSMN NewsFeed - 23 Feb 2010
TopoTarget Announces New CEO to Prepare Commercialisation of Belinostat
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Nov 2009
Ismail Kola joins UCB as Executive Vice President, UCB & President of UCB New Medicines(TM)
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Dec 2008
ICON Medical Imaging Launches New Cardiac Echocardiography Analysis Software
Devices Cardiology
 HSMN NewsFeed - 17 Sep 2008
Cambridge Laboratories Announces New Marketing Arrangements for XENAZINE(R) in North America
Biopharmaceuticals Neurology
 HSMN NewsFeed - 19 Sep 2007
Evotec to Acquire Renovis, Seek NASDAQ Listing
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 16 Aug 2007
Philips to Acquire Healthcare Informatics Company XIMIS Inc. to Strengthen Presence in the Healthcare Information Technology Market
Devices Radiology Mergers & Acquisitions
 HSMN NewsFeed - 20 Jun 2007
Shire In-Licenses JUVISTA(R) (Human TGFbeta3) From Renovo
Biopharmaceuticals Licensing
 HSMN NewsFeed - 11 Jan 2007
The European Commission Approves First and Only Enzyme Replacement Therapy for Hunter Syndrome
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 4 Dec 2006
Risk of Heart Attack Significantly Reduced in About 90 days by Modern Combination of Drugs
Biopharmaceuticals Cardiology
Return to NewsFeed  

 Additional items found! 10

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 10 additional stories matching:
XIMIS
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.